Survival at 15 months mos and growing weekly at two institutions in the North East (granted these are the Bavituximab treated patients ) it goes without saying Peregrine is in the drivers seat.
Are the other 156 trial sites trending as these two are?
The share price is literally nauseating I can't even look at it anymore. The value of our stock should match the value of this life extending life saving technology in the near term. The disconnect is actually beyond belief so much so that it makes one question does Bavi work?
That answer is the easy one here.
The hard question is when will the value of the stock match the IP?
Does first look start the value? I thought so four months ago but will be pleasantly surprised if it does. Does Yervoy Bavituximab melanoma data set the price? Again I thought so months ago.
So what's left? Fully enrolled sunrise that should get the ball rolling. Should :)
Trial halt or major partner with big money are the only two variables that snap our deep capture imo. From there we will be valued north of 4 billion.
On the bright side were now weeks to six months away.
News 
Market Data 
Discover 
